annb0t
Top 20
SYDNEY, Dec. 15, 2022 /PRNewswire/ --Â Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to explore novel uses of paxalisib in solid tumours. Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)
The research project is led by Professor Sudha Rao, a leading expert in transcriptional biolog...
>>> Read more: KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
The research project is led by Professor Sudha Rao, a leading expert in transcriptional biolog...
>>> Read more: KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
